Royalty Pharma (RPRX) PT Raised to $38 at UBS, But Firm on Sidelines Due to Structural Issues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 66.40 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.40 | 52 Week High | $3.48 | |||
| Open | $66.40 | 52 Week Low | $0.80 | |||
| Day High | $66.40 | P/E | N/A | |||
| Day Low | $66.40 | EPS | $-1.54 | |||
| Volume | 1 | |||||
